Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Case Report

Published on 03 Jul 2025

Severe hypotension induced by Almonertinib: a case report with literature review and clinical insights

in Cancer Molecular Targets and Therapeutics

Haiyu Niu
Feixue Song
Xiaochun Zhou
Qiaoying Jin
Yating Liu
Benxin Luo
Hanwen Wei

Frontiers in Oncology

doi 10.3389/fonc.2025.1566768

119 views

Review

Published on 02 Jul 2025

USP39: a key regulator in malignant tumor progression

in Cancer Molecular Targets and Therapeutics

Junyan Li
Jinghua Zhong
Jianming Ye
Yi Xiang
Xiangcai Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1556011

137 views

Correction

Published on 02 Jul 2025

Correction: FGFR3-TACC3 fusion gene promotes glioblastoma malignant progression through the activation of STAT3 signaling pathway

in Cancer Molecular Targets and Therapeutics

Yiming Li
Jianshen Liang
Xiude Ren
Jiahe Guo
Xisen Wang
Xuya Wang
Shengping Yu
Tao Li
Xuejun Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1637363

298 views

Original Research

Accepted on 01 Jul 2025

Cost-Effectiveness Analysis of Belzutifan for Advanced Renal Cell Carcinoma

in Cancer Molecular Targets and Therapeutics

Guangpeng Chen
Li Luo
Wenting Zhu

Frontiers in Oncology

doi 10.3389/fonc.2025.1556394

Original Research

Published on 01 Jul 2025

Mapping the knowledge network of extracellular vesicles and angiogenesis in tumor-immune communication: a scientometric analysis

in Cancer Molecular Targets and Therapeutics

Kai Wang
Dufu Lu

Frontiers in Oncology

doi 10.3389/fonc.2025.1568365

236 views

Mini Review

Accepted on 30 Jun 2025

Exploring MicroRNA Targeting as a Promising Approach for Solid Tumor Treatment

in Cancer Molecular Targets and Therapeutics

Vahidreza Karamad
Maryam Amiri
Amir Kian Moaveni
Behrouz Shademan
Alireza Nourazarian
Cigir Biray

Frontiers in Oncology

doi 10.3389/fonc.2025.1570093

Original Research

Accepted on 30 Jun 2025

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying High-Grade Serous Ovarian Cancer

in Cancer Molecular Targets and Therapeutics

Elena Conca
Daniele Lorenzini
Emanuela Minna
Luca Agnelli
Matteo Duca
Marco Gentili
Beatrice Bodini
Maggie Polignano
Mara Mantiero
Silvia Damian

Frontiers in Oncology

doi 10.3389/fonc.2025.1633410

Review

Accepted on 30 Jun 2025

Polyploid Giant Cancer Cells and Tumor Budding: Translation from Basic Research to Clinical Application

in Cancer Molecular Targets and Therapeutics

Peng Huang
Rong Wu
Zhimou Yang
Yuwei Li
Fei Fei
Yongjun Yu

Frontiers in Oncology

doi 10.3389/fonc.2025.1611920

Original Research

Published on 30 Jun 2025

PALB2 deficiency may sensitize H3K27M-mutant pediatric HGG cells to BMN673/talazoparib

in Cancer Molecular Targets and Therapeutics

Xiaowen Guan
Xinke Xu
Xiaolan Mo
Houliang Deng

Frontiers in Oncology

doi 10.3389/fonc.2025.1589396

365 views

Original Research

Published on 30 Jun 2025

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer

in Cancer Molecular Targets and Therapeutics

Fang Zhou
Shushu Liu
Ying Zuo
Danial F. Naseem
Yinguang Li
Yin Wang
Cuicui Meng
Yipeng Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1614434

324 views

Review

Published on 27 Jun 2025

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation

in Cancer Molecular Targets and Therapeutics

Jiaqi Tian
Miaomiao Han
Fuyang Song
Yun Liu
Yuhou Shen
Jiateng Zhong

Frontiers in Oncology

doi 10.3389/fonc.2025.1576781

305 views

Original Research

Accepted on 26 Jun 2025

Elevated Plasma Levels of WAP Four-Disulfide Core Domain 2 as a Potential Prognostic Biomarker for Various Cancers

in Cancer Molecular Targets and Therapeutics

Makoto Watanabe
Katsuaki Ieguchi
Nobuyuki Onishi
Takashi Shimizu
Ryotaro Ohkuma
Risako Suzuki
Emiko Mura
Nana Iriguchi
Tomoyuki Ishiguro
Yuya Hirasawa

Frontiers in Oncology

doi 10.3389/fonc.2025.1614102

212 views

Editorial

Accepted on 26 Jun 2025

Editorial: "Advancements in Drug Development: Exploring Bi-Specific Antibodies as Promising Therapeutic Strategies in Oncology"

in Cancer Molecular Targets and Therapeutics

Urs Michael Weber
Julie Bailis
Angela Coxon
Sharon R Pine
Giuseppe Giaccone

Frontiers in Oncology

doi 10.3389/fonc.2025.1651944

143 views

Technology and Code

Accepted on 26 Jun 2025

A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer

in Cancer Molecular Targets and Therapeutics

Amith Rangarajan
Ilona Sviezhentseva
Emma Gunderson
Yana Pikman
Matthew P Jacobson
Beth Apsel Winger

Frontiers in Oncology

doi 10.3389/fonc.2025.1599389

Original Research

Published on 25 Jun 2025

Multidimensional analysis suggests that ZNF433 is a promising biomarker for the diagnosis and prognosis of human cancers

in Cancer Molecular Targets and Therapeutics

Lingyu Xie
Xin Zeng
Hui Luo
Bin Xie
Xuefeng Wang
Nan Wu
Junrong Zou
Guoxi Zhang
Xiaofeng Zou
Hui Xu

Frontiers in Oncology

doi 10.3389/fonc.2025.1584042

445 views

Original Research

Published on 25 Jun 2025

Exploration of the role and mechanism of Rhizoma Paridis total saponins in osteosarcoma based on SPI1/LCN2-mediated ferroptosis

in Cancer Molecular Targets and Therapeutics

Ge Yang
Fenghui Li
Xiongke Hu
Miao Li
Yaoxi Liu
Guanghui Zhu
Qian Tan

Frontiers in Oncology

doi 10.3389/fonc.2025.1592862

299 views